NYSE:WATWaters Stock Price, Forecast & News

Waters' stock was trading at $184.10 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, WAT stock has increased by 2.5% and is now trading at $188.75. View which stocks have been most impacted by Coronavirus.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Waters in the last year. There are currently 5 sell ratings and 4 hold ratings for the stock, resulting in a consensus recommendation of "Sell." View analyst ratings for Waters.

Waters is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Waters.

Waters Co. (NYSE:WAT) announced its quarterly earnings data on Tuesday, April, 28th. The medical instruments supplier reported $1.15 EPS for the quarter, missing analysts' consensus estimates of $1.39 by $0.24. The medical instruments supplier earned $464.94 million during the quarter, compared to analyst estimates of $480.07 million. Waters had a return on equity of 1,937.83% and a net margin of 22.77%. Waters's revenue was down 9.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.60 EPS. View Waters' earnings history.

9 brokerages have issued 12 month price targets for Waters' stock. Their forecasts range from $145.00 to $212.00. On average, they anticipate Waters' stock price to reach $176.38 in the next twelve months. This suggests that the stock has a possible downside of 6.6%. View analysts' price targets for Waters.

Media stories about WAT stock have been trending somewhat negative recently, InfoTrie reports. The research firm ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Waters earned a news sentiment score of -1.2 on InfoTrie's scale. They also assigned news articles about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news about Waters.

Waters saw a decrease in short interest in the month of June. As of June 30th, there was short interest totaling 4,310,000 shares, a decrease of 6.7% from the June 15th total of 4,620,000 shares. Based on an average daily trading volume, of 580,300 shares, the short-interest ratio is presently 7.4 days. Currently, 7.0% of the shares of the stock are sold short. View Waters' Current Options Chain.

Some companies that are related to Waters include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Bio-Rad Laboratories (BIO), PerkinElmer (PKI), BIO-TECHNE (TECH), Charles River Laboratories Intl. (CRL), Bruker (BRKR), Luminex (LMNX), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO), aTyr Pharma (LIFE) and BG Medicine (BGMD). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Waters investors own include Thermo Fisher Scientific (TMO), Honeywell International (HON), Home Depot (HD), CVS Health (CVS), Raytheon Technologies (RTX), Alibaba Group (BABA), Verizon Communications (VZ), Cisco Systems (CSCO), Walmart (WMT) and CSX (CSX).

Waters trades on the New York Stock Exchange (NYSE) under the ticker symbol "WAT."

Waters' stock is owned by a variety of institutional and retail investors. Top institutional investors include Robecosam AG (0.34%), Mountain Pacific Investment Advisers Inc. ID (0.07%), Independent Investors Inc. (0.07%), Envestnet Asset Management Inc. (0.05%), State of Alaska Department of Revenue (0.05%) and Diversified Trust Co (0.01%). Company insiders that own Waters stock include Christopher A Kuebler, Edward Conard, Elizabeth B Rae, Francis Kim, Ian King, Joann A Reed, Keeley A Aleman, Laurie H MD Glimcher, Mark T Beaudouin, Michael C Harrington, Michael F Silveira, Michael J Berendt, Robert G Carson, Terrence P Kelly and Thomas P Salice. View institutional ownership trends for Waters.

WAT stock was sold by a variety of institutional investors in the last quarter, including Mountain Pacific Investment Advisers Inc. ID, Independent Investors Inc., and IBM Retirement Fund. Company insiders that have sold Waters company stock in the last year include Edward Conard, Elizabeth B Rae, Francis Kim, Ian King, Joann A Reed, Keeley A Aleman, Laurie H MD Glimcher, and Mark T Beaudouin. View insider buying and selling activity for Waters.

WAT stock was bought by a variety of institutional investors in the last quarter, including Robecosam AG, State of Alaska Department of Revenue, Cypress Capital Group, Envestnet Asset Management Inc., Diversified Trust Co, and Fulton Bank N. A.. View insider buying and selling activity for Waters.

Shares of WAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of WAT stock can currently be purchased for approximately $188.75.

Waters has a market capitalization of $11.69 billion and generates $2.41 billion in revenue each year. The medical instruments supplier earns $592.20 million in net income (profit) each year or $8.99 on an earnings per share basis. Waters employs 7,500 workers across the globe.

The official website for Waters is www.waters.com.

Waters' mailing address is 34 MAPLE STREET, MILFORD MA, 01757. The medical instruments supplier can be reached via phone at 508-478-2000 or via email at [email protected]